The Pathology of Hereditary Breast Cancer by unknown
Hereditary Cancer in Clinical Practice 2004; 2(3) 131
Hereditary Cancer in Clinical Practice 2004; 2(3) pp. 131-138
Abstract
Several studies have demonstrated that familial breast cancers associated with BRCA1 or BRCA2 germline
mutations differ in their morphological and immunohistochemical characteristics. Cancers associated with
BRCA1 are poorly differentiated infiltrating ductal carcinomas (IDCs) with higher mitotic counts and pleomorphism
and less tubule formation than sporadic tumours. In addition, more cases with the morphological features of
typical or atypical medullary carcinoma are seen in these patients. Breast carcinomas from BRCA2 mutation
carriers tend to be of higher grade than sporadic age-matched controls. Regarding immunophenotypic features.
BRCA1 tumours have been found to be more frequently oestrogen receptor- (ER) and progesterone receptor-
(PR) negative, and p53-positive than age-matched controls, whereas these differences are not usually found in
BRCA2-associated tumours. A higher frequency and unusual location of p53 mutations have been described
in BRCA1/2 carcinomas. Furthermore, BRCA1- and BRCA2-associated breast carcinomas show a low frequency
of HER-2 expression. Recent studies have shown that most BRCA1 carcinomas belong to the basal cell phenotype,
a subtype of high grade, highly proliferating ER/HER2-negative breast carcinoma characterized by the expression
of basal or myoepithelial markers, such as basal keratins, P-cadherin, EGFR, etc. This phenotype occurs with
a higher incidence in BRCA1 tumours than in sporadic carcinomas and is rarely found in BRCA2 carcinomas.
Hereditary carcinomas not attributable to BRCA1/2 mutations have phenotypic similarities with BRCA2 tumours,
but tend to be of lesser grade and lower proliferation index. The pathological features of hereditary breast
cancer can drive specific treatment and influence the process of mutation screening. 
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Introduction
It is currently estimated that 5-10% of all breast
cancers are hereditary and attributable to mutations
in several highly penetrant susceptibility genes, of
which only two have been identified: BRCA1 (OMIM
113705) [1] and BRCA2 (OMIM 600185) [2]. Earlier
estimates suggested that BRCA1 and BRCA2 mutations
were responsible for 75% of site-specific breast cancer
families and the majority of breast and ovarian cancer
families [3, 4]. Recent data shows however that these
percentages may have been overestimated and that
the proportion of families classified due to mutations
in BRCA1 or BRCA2 is much lower and strongly
depends on the population analyzed [5] and the
specific characteristics of the selected families [6, 7].
In fact, the percentage of high risk families associated
with mutations in these genes is very similar (around
25%) in all series, including the one we have found
in Spain [8, 9]. 
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Table 1. Morphological and immunohistochemical profiles associated with hereditary breast cancer tumours
GRADE RE RP BCL2 P53 Ki-67 Cyclin D1 CK5/6
BRCA1 3 – – – ++ ++ – +
BRCA2 2/3 + + + + + ± – 
non-BRCA1/2 1/2 + + + – – + –
Genetic testing for BRCA1 and BRCA2 is expensive
and time-consuming due to the large size of both
genes, the absence of hot spots for mutations
throughout their entire coding regions, and the low
percentage of mutated cases. It is therefore important
to find clinical or pathological factors that could
suggest or exclude the presence of BRCA1 or BRCA2
mutations in a given patient. 
The histopathology of BRCA-associated cancer has
been studied by different groups; however the larger
series are those reported by the Breast Cancer Linkage
Consortium (BCLC) [10-12]. These studies have
demonstrated that cancer arising in carriers of
mutations in either the BRCA1 or BRCA2 genes differs
morphologically from sporadic breast cancers from
age-matched controls [11-14]. In addition, numerous
immunohistochemical studies have tried to better
characterize the differences between hereditary and
sporadic tumours [10, 15-18]. More recently, some
reports have also described the pathology of hereditary
breast cancer not attributable to BRCA1 or BRCA2
germline mutations. The purpose of this review is to
present the histopathological characteristic of different
genotypes of hereditary breast cancer. Special attention
will be given to those characteristics that possibly
impact on genetic testing, prognosis and treatment. 
Histopathology of BRCA1 and BRCA2
breast cancer
In order to better understand the specific characteristics
of hereditary breast cancer, the histopathological and
immunohistochemical variables usually evaluated in
sporadic breast cancer are also presented, since invasive
breast carcinoma is a heterogeneous group of malignant
epithelial tumours with a wide range of morphological
phenotypes and specific histopathological types. 
Histological type
Invasive ductal carcinoma (IDC) not otherwise
specified (NOS) is the most common histological type
among sporadic breast cancer, comprising 70-80% of
all cases. The most frequent special histological types are
invasive lobular carcinoma (5-15%), tubular carcinoma
(2%), invasive cribriform carcinoma (0.8-3.5%), medullary
carcinoma (1-7%), mucin producing carcinoma (2%),
neuroendocrine tumours (2-5%), invasive micropapillar
carcinoma (2%). Differences between series are related
with the specific population studied or, more probably,
with stringency in the application of diagnostic criteria. 
Medullary carcinoma is a particular type of
carcinoma characterized by the presence of solid sheets
of large and pleomorphic cells with indistinct cell borders
that lead to a syncytial appearance [19]. They are
high-grade tumours with numerous mitosis, and sparse
necrosis (<25%). The border of the tumour is well
defined with a pushing edge. The stroma is a dense
lymphocytic infiltrate. Despite being a high-grade tumour,
it has been associated with a relatively favourable
prognosis [19-21]. Atypical medullary carcinoma is
diagnosed when more than 25% of tumour is not
classical medullary or the lymphoid infiltration is
moderate or the circumscription is not complete. 
IDC NOS is the most common histological type in all
forms of hereditary breast cancer and it seems to be
significantly more frequent in BRCA1 and BRCA2 mutation
carriers than in non-carriers [22]. In addition, BRCA1
mutation carriers have a higher incidence of medullary
carcinoma (13%) than BRCA2 mutation carriers (3%) and
non-carriers (2%) [12]. When only IDC cases are
compared, after excluding medullary carcinomas, BRCA1
tumours have more frequently a prominent lymphocytic
infiltrate and pushing margins [11], some of the features
that define the medullary histotype. 
Regarding BRCA2 carcinomas, Marcus et al have
reported a higher incidence of BRCA2 tumours belonging
to a ”tubular lobular group”, including invasive lobular,
tubular and cribriform carcinomas [23, 24]. Armes et al
found that BRCA2 mutation carriers showed an excess of
pleomorphic lobular and intraductal carcinomas [13].
However, other series have not found any statistically
significant difference in the histological type of BRCA2
with respect to controls [11, 12, 25]. 
Histological grade
Breast carcinomas are routinely graded based on an
assessment of tubule formation, nuclear pleomorphism
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and mitotic counts. This method of tumour graduation
consists of scoring 1-3 for each factor. The grade is
obtained by adding the three previous parameters and
classifying the tumour as grade 1 (well differentiated
or low-grade), grade 2 (moderately differentiated or
intermediate-grade) and grade 3 (poorly differentiated
or high-grade). This grading system has prognostic
implications and the utility has been convincingly
proved [26, 27]. 
BRCA1 tumours are more frequently high-grade
(grade 3) tumours because they show less tubule
formation, higher pleomorphism and a higher number
of mitosis than sporadic age-matched breast cancer
controls. Thus, the reported incidence of grade 3 tumours
in BRCA1 mutation carriers ranged from 66% to 84% in
different studies [12, 28, 29] while the proportion of grade
3 tumours in sporadic age-matched breast cancer
controls was between 30% and 40% [12, 28, 29]. 
BRCA2 tumours tend to be of higher grade than
sporadic controls, although this association is less
strong than for BRCA1 cases. Most BRCA2 tumours
are grade 2/3, and show less tubule formation but
similar cellular pleomorphism and mitotic count than
sporadic cases [12]. Furthermore this difference in
tubule formation, Agnarsson et al [25] have reported
more nuclear pleomorphism and higher mitotic rates
in BRCA2 tumours than in sporadic tumours. 
Hormone receptors and associated markers
Sporadic breast cancer tumours express a number
of immunohistochemical markers that provide prognostic
and predictive information about these tumours. In this
sense, approximately 70% of breast carcinomas express
the oestrogen receptor (ER) protein and 50% are
progesterone receptor- (PR) positive. ER-positive tumours
are more frequently well or moderately differentiated,
p53- and HER2-negative and have a lower proliferation
rate and better overall survival, but do not have a lower
metastatic potential. ER-positive and PR-positive tumours
respond to anti-oestrogen treatment in approximately
75% of the cases. The response is 34% when the tumour
is ER-positive and PR-negative, and 45% in the case of
ER-negative and PR-positive tumours. Only a small
proportion of ER-negative and PR-negative (<10%)
respond to anti-oestrogens, perhaps reflecting false
negative ER measurement [30]. 
Many authors have emphasized the high frequency
of ER-negativity in BRCA1 tumours, [10, 18, 28, 29,
31-34]. Between 73% and 90% [28, 29, 31] of BRCA1
carcinomas have been reported to be ER-negative in
different series. Although it has been suggested that
this relationship might be explained by the higher grade
of tumours and younger age of patients, BRCA1
tumours are more likely ER-negative than sporadic
ones, when tumours from patients at the same age are
compared. In addition, the likelihood of ER-negativity
is 4.8 times higher in BRCA1 grade 3 tumours when
they are compared with grade 3 sporadic cases [18].
In this sense, for example, Lakhani et al [10] reported
that 90% of BRCA1-related breast cancers were
ER-negative compared with 35% in controls. 
PR expression in BRCA1 tumours is also lower than
in sporadic tumours. In the study of Lakhani et al [10]
79% of BRCA1 tumours were PR-negative compared
with 41% in sporadic tumours. The same proportion
has been observed in other publications [28, 29, 31]. 
In contrast to BRCA1 tumours, those arising in
BRCA2 mutation carriers do not differ from controls
with regard to ER and PR expression. Thus, ER
expression has been reported in around 65% of BRCA2
tumours [10, 31, 32]. Between 40% and 60% of
BRCA2 carcinomas expressed PR [10, 31, 32]. 
Taking into account the differences in hormone
receptor status between BRCA1 and BRCA2 tumours,
it is not surprising that the expression of some markers
is consistently associated with hormone receptors in
breast cancer, such as Bcl-2 and cyclin D1, and differ
between both genotypes. Bcl-2 is a protein that inhibits
programmed cell death (apoptosis). This protein is
detected in 50-90% of IDC of the breast [35, 36]. Bcl-
2 expression is associated with favourable
clinicopathological features [37]. Thus, it is more
frequently present in well-differentiated ER-positive
breast carcinomas. Bcl-2-positive p53-negative tumours
have a better response to hormonal therapy than bcl-
2-negative p53-positive ones [35]. Bcl-2 has a low rate
of expression in BRCA1-associated tumours (31%) with
respect to sporadic carcinomas [28, 38], but there are
no statistically significant differences between BRCA2
and sporadic tumours [38]. 
Cyclin D1 plays an important role in cell cycle
progression during G1 phase. Cyclin D1 is considered
a potential oncogene and is amplified in about 15%
of IDCs [39]. Cyclin D1 is known to be upregulated by
oestrogen and progesterone and to be downregulated
by anti-oestrogens [40]. The cyclin D1 protein is
detected in 50% of cases [41] and its expression is
associated with low histological grade, ER positivity and
good prognosis. Several series have detected lower
cyclin D1 expression levels in BRCA1 (5% and 33%)
than in sporadic tumours [31, 33, 42]. Cyclin D1
expression in BRCA2 tumours has been found at an
intermediate level between BRCA1 and sporadic
tumours. Osin et al [33] reported that 27% of BRCA2
tumours expressed cyclin D1 compared with 5% in
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BRCA1 tumours, and 35% in sporadic tumours. In the
same way, Armes et al [31] has shown cyclin D1
positivity in 55% of BRCA2, 33% of BRCA1 and 100%
of sporadic tumours. 
p53 expression and gene mutations
Around 15% to 30% of sporadic breast carcinomas
have mutations in the tumour suppressor gene p53.
Most of them are missense mutations that result in the
accumulation of stable p53 protein that can be
visualized by immunohistochemistry. However, 20% of
the mutations do not yield a stable protein and it is not
detected by immunostaining. For this reason, a stronger
association between clinicopathological variables and
p53 mutations, detected by DNA sequencing has been
shown rather than with p53 immunohistochemistry
detection in breast cancer. 
Several studies have demonstrated a high incidence
of p53 immunostaining in BRCA1 when compared to
sporadic cases. p53 over-expression has been detected
in 45% to 77% of BRCA1-associated tumours [10, 28,
29, 43, 44]. The results in BRCA2 tumours are
inconclusive [10]. Some studies have found p53 over-
expression in around 50% of BRCA2 carcinomas,
whereas in other series the percentage was lower than
20% [28]. 
The importance of p53 inactivation in
BRCA-associated tumours is also supported by genetic
studies demonstrating a higher frequency and unusual
location of p53 mutations in this group when compared
with sporadic cases [43-45]. In a review of reported cases
by Chappuis et al [22] around 40% of BRCA1 and 30%
of BRCA2 carcinomas had p53 mutations whereas it was
found in only about 20% of sporadic controls. When
comparing the spectrum of p53 mutations in BRCA1/2
patients with those reported in the IARC p53 mutation
database, Greenblatt et al [46] found that they differed
significantly both in distribution and in base changes.
Mutations at A:T bp were common in BRCA1/2-
associated tumours. Changes were frequent at p53
codons that are not mutation hotspots and were located
at the opposite side of the p53 DNA-binding site. 
HER2 expression and gene amplification
HER2 is the human epidermal growth factor
receptor-2 that encodes a transmembrane glycoprotein
with intrinsic tyrosine kinase activity. HER2 gene is located
in chromosome 17q12 and has been associated with
poor outcome and poor response to anti-oestrogens,
but a better response to anthracyclines. Over-expression
of HER-2 is identified in 10% to 34% of primary breast
tumours [47, 48] and is attributable to gene
amplification in approximately 90% of cases [49, 50].
The humanized anti-HER-2 monoclonal antibody,
Herceptin, has been shown to be effective in 20% of
patients with HER-2 amplification. 
Data regarding HER2 expression in BRCA-associated
tumours vary among series, probably indicating technical
issues. For example, Armes et al [31] have shown no
differences in strong expression of HER-2 between BRCA2
and sporadic breast tumours, 44% and 45% respectively,
but they did not find HER-2 expression in any BRCA1
tumours. However, subsequent studies have observed
HER2 over-expression in up to 3% in both BRCA1 and
BRCA2 tumours [10, 28, 51]. With regard to the HER-2
amplification, only two studies have analyzed gene status
by FISH in hereditary BRCA1-associated carcinomas [28,
52], and only one in BRCA2-associated carcinomas.
According to immunohistochemistry data, high level of
HER-2 amplification (>2.4 copies) has not been reported
in BRCA1 and BRCA2 tumours. 
BRCA1 carcinomas and the basal cell phenotype 
Sorlie et al [53, 54] using cDNA microarrays classified
breast tumours into clinically relevant subgroups. They
defined different subtypes of breast tumours, including
two non-overlapping groups of ER-negative carcinomas:
the basal like and the ERBB2 over-expressing groups.
The basal cell phenotype is characterized by the
expression of markers that are usually expressed by the
basal or myoepithelial cells of the normal breast. The
group of myoepithelial/basal markers include the basal
epithelial keratins (CK) 5/6, 14, and 17, muscle-specific
actin, P-cadherin, S100, CD10, caldesmon, calponin,
EGFR etc. [55-57]. The existence of a group of breast
carcinomas with a basal cell phenotype has been
confirmed by other groups using DNA microarray and
immunohistochemical approaches [58-60]. Some of
these studies have also indicated the poor prognosis of
this group of neoplasias [17, 55, 56]. 
Recently Sorlie et al [53] reanalyzing cDNA
microarray data from van’t Veer et al [61], that included
18 BRCA1 and 2 BRCA2 carcinomas, observed that
80% of BRCA1 carcinomas had a basal epithelial type
gene expression profile. Subsequently, Foulkes et al and
Palacios et al have found a high prevalence of tumours
with a basal phenotype among BRCA1 mutation
carriers. For example, Palacios et al [60] reported that
CK 5/6 was expressed in 50% of BRCA1 tumours but
in less than 10% of BRCA2 cases and sporadic controls.
In addition this phenotype is characterized by ER and
HER2 negativity and the expression of specific cell cycle
markers, such as over-expression of cyclin E and
down-regulation of p27. Interestingly, a high proportion
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(60%) of BRCA1 carcinomas have been reported to
over-express EGFR [10, 16, 57, 60, 62]. 
Histopathology of familial non-BRCA1/2
tumours
There are two studies that have defined the
histological characteristics of these neoplasias [28, 63].
This group of tumours represents 67% of familial breast
cancer when families with only female breast cancer
and 4-5 affected members are considered [6]. In the
Spanish population, when considering families with at
least three cases of female breast cancer and one of
them <50 years, the percentage of cases non-
attributable to BRCA1/2 mutation was 75% [8]. 
IDC is the most frequent histological type in familial
non-BRCA1/2: 77% of the cases according to Lakhani
et al [63] and 78% in the series by Palacios et al [28].
An excess of lobular carcinomas was found in familial
non-BRCA1/2 (15%) when compared with BRCA1 (3%),
BRCA2 (9%) and sporadic cases (10%). The difference
was only significant with respect to BRCA1 tumours [63]. 
Breast cancers from familial non-BRCA1/2 patients
were of lesser histological grade than BRCA1/2-
associated tumours [28, 63]. Thus, grade 1 tumours
accounted for 27% to 50% in total. In addition,
non-BRCA1/2 tumours showed more tubule formation,
a lower mitotic index and lesser pleomorphism than
BRCA1/2-associated carcinomas [28, 63]. 
In the only immunohistochemical study in familial
non-BRCA1/2 [28], these tumours were more frequently
ER- (75%), PR- (67%), and BCL2-positive (55%), but
p53-negative (3.7%); these figures clearly differed from
BRCA1 tumours, but no significant differences were
found with respect to BRCA2 carcinomas. A low
incidence of HER2 expression and amplification (4%)
was found in non-BRCA1/2 carcinomas [28]. 
Pathology findings in prophylactic 
mastectomy specimens from BRCA1/2 
mutation carriers
The natural history of hereditary breast cancer from
morphologically normal epithelium to invasive disease
is not well understood. The incidence of in situ lesions
associated with invasive carcinomas is poorly described
in most publications. Overall, an in situ component is
less common around IDC in BRCA1 mutation carriers
than in controls [12]. In addition, the incidence of in
situ lesions in the absence of an invasive component
in familial breast cancer is not established. 
The study of prophylactic mastectomy specimens
from BRCA1/2 mutation carriers has been proposed
as a means to better understand the different stages of
breast cancer development in these patients. However,
the lack of data available is not conclusive due to the
low number of case studies and the difficulty in
selecting appropriate controls which is confounded by
difficulties in recognizing precursor lesions. 
Hoogerbrugge et al have reported a study with 67
patients at high risk of breast cancer, 44 of them with
BRCA mutation, who underwent unilateral or bilateral
prophylactic mastectomy. One or more different types
of high-risk precursor lesions were present in 57% of
the women: 37% had atypical lobular hyperplasia (ALH),
39% atypical ductal hyperplasia (ADH), 25% lobular
carcinoma in situ (LCIS), and 15% ductal carcinoma in
situ (DCIS). A 4-mm invasive ductal carcinoma was
found in one woman with ductal carcinoma in situ. Prior
to mastectomy, palpation or mammography was
performed and none of these lesions were detected.
These high risk lesions were more frequent in the group
of women aged 40 years and older (73% vs. 43%) and
less frequent in BRCA mutation carriers (43%) and
women who had undergone bilateral oophorectomy
before prophylactic mastectomy (20%) [64]. 
In another study, Kauff et al [65] compared
prophylactic mastectomy specimens from 24 women
with BRCA mutations and 48 controls extracted from an
autopsy registry, concluding that BRCA mutation carriers
have a higher incidence of high risk lesions including
DCIS, LCIS, ADH or ALH (46%) compared to control
cases (6%). 
Adem et al [66] compared prophylactic mastectomy
from patients with a family history of breast cancer
including 28 BRCA1/2 mutation carriers, 117 women
without BRCA1/2 mutation, 12 unclassified mutation
variant carriers, and 283 sporadic control cases. They
found similar prevalence of DCIS in all groups 53%, 60%,
56%, 55%, respectively. However, in BRCA1/2 mutation
carriers, the prevalence of proliferative fibrocystic changes
was lower (7%) compared with 25% in sporadic cases.
In contrast, the proportion of invasive carcinomas was
higher in mutation and unclassified variant alteration
carriers compared with the control group and the
mutation negative group, suggesting a faster progression
of precursor lesions in mutation carriers. 
Genetic testing and therapeutic implications
Available data concerning morphological and
immunohistochemical characteristics of hereditary
breast cancer demonstrated major differences between
genotypes. The most important differences were found
between tumours in BRCA1 carriers and all other
categories. These histopathological features in
conjunction with clinical data can be used to predict
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BRCA1 status and to a lesser extent BRCA2 and
non-BRCA1/2 status and this could have implications
for the process of mutation screening. 
In this sense, it has been suggested that the
immunohistochemical analysis of ER, together with age
and histological grade, provides a new powerful
predictor of BRCA1 mutation status. It has been
estimated that the probability of a woman with familial
breast cancer diagnosed before 35 years to be
a BRCA1 mutation carrier is 25% if the tumour is grade
3 and ER-negative but the probability is only 5% if the
tumour is ER-positive [10]. Taken into account the high
proportion of BRCA1 carcinomas that express basal
markers (i.e. CK 5/6), it is likely that the addition of
such markers in the pathological study will improve
our ability to predict the BRCA1 genotype. 
Alternatively, if we have a tumour which is high grade
(grade 2-3), ER-, and PR-positive and CK5/6-negative
in a family with more than six female breast cancers in
the first and second generations, early-onset prostate
cancer or male breast cancer, it is likely we are dealing
with a BRCA2 tumour. 
Finally, it is very rare to find a BRCA1 or BRCA2
mutation when we are confronted with a low grade
tumour (grade 1) with high tubule formation, ER- and
PR-positive and p53-negative and a very low proliferation
index. The probability of being a non-BRCA1/2 tumour
increases if there are between three and six female breast
cancer cases in the family, without ovarian cancer or early
onset prostate cancer. In such a situation, probably it
would be sufficient to study only the more recurrent
mutations in each population in order to reduce the
possibility of leaving atypical positive cases without
diagnosis. 
From a therapeutic point of view, adjuvant hormone
therapy is not indicated in most BRCA1 tumours, since
they are ER- and PR-negative, but can be used in most
BRCA2 and non-BRCA1/2 carcinomas. The use of
hormone therapy as chemopreventive drugs in BRCA1
patients is debatable [18, 32, 67-70]. Taking into
account the low incidence of HER2 amplification/over-
expression in most hereditary breast cancer, these
tumours are not good candidates for treatment with
Herceptin. However, the high incidence of EGFR
recently reported in BRCA1 tumour [62] opens the
possibility that these women can be treated with specific
compounds, such as tyrosine kinase inhibitors or anti-
EGFR monoclonal antibodies. 
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